Biophytis

Biophytis P/TBV

The Price to Tangible Book Value (P/TBV) of Biophytis (ALBPS.PA) as of Nov 3, 2026 is -0.19. In the previous year, Price to Tangible Book Value (P/TBV) was -0.37 — a change of -47.11% (higher).

P/TBV

-0.19

YoY

-47.11%

Last updated:

Price to Tangible Book Value (P/TBV) of Biophytis is 2024 -0.19 . Price to Tangible Book Value (P/TBV) of Biophytis was 2023 -0.37 . It decreases by -47.11% higher compared to the previous year.

The Biophytis P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2017
0.12 EUR
Jan 1, 2018
0.46 EUR
Jan 1, 2019
-0.24 EUR
Jan 1, 2020
-6.36 EUR
Jan 1, 2021
0.77 EUR
Jan 1, 2022
-0.52 EUR
Jan 1, 2023
-0.37 EUR
Jan 1, 2024
-0.19 EUR
The Biophytis P/TBV history
YEARP/TBVYoY
-0.19-47.11%
-0.37-30.18%
-0.52-167.89%
0.77-112.15%
-6.36+2,557.75%
-0.24-151.58%
0.46+274.64%
0.12-87.38%
0.98+289.98%
0.25-111.62%
-2.16—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biophytis Stock analysis

What does Biophytis do? Biophytis SA develops therapeutics for sarcopenia and Age Related Macular Degeneration, focusing on restoring muscular and visual functions. The company's clinical programs include Sarconeos (BIO101) for sarcopenia and Macuneos (BIO201) for ARMD, developed simultaneously in the U.S. and domestic markets. Biophytis generates revenue through clinical development partnerships and potential future product sales, targeting pharmaceutical companies and healthcare providers seeking treatments for aging-related conditions. The company's primary products are Sarconeos (BIO101) and Macuneos (BIO201), with clinical development ongoing for both. Biophytis targets healthcare providers and pharmaceutical companies as key buyers, particularly those focused on aging diseases. The firm's strategy involves advancing drug candidates through clinical trials to secure regulatory approvals and commercial partnerships. Biophytis SA's business model centers on the development of two drug candidates, Sarconeos (BIO101) and Macuneos (BIO201), for sarcopenia and ARMD respectively. The company's revenue streams are derived from clinical development collaborations and potential future licensing agreements with pharmaceutical firms. The target market comprises healthcare institutions and pharmaceutical companies seeking innovative treatments for age-related medical conditions. Biophytis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biophytis stock

Price to Tangible Book Value (P/TBV) of Biophytis is -0.19 in 2024.

Price to Tangible Book Value (P/TBV) of Biophytis changed from -0.37 to -0.19, representing a -47.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Biophytis since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Biophytis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biophytis

All Key Metrics — Biophytis